Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alkermes Plc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ALKS
Nasdaq
2834
https://www.alkermes.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alkermes Plc
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
- May 15th, 2024 4:14 pm
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
- May 14th, 2024 11:00 am
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
- May 2nd, 2024 3:39 pm
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
- May 2nd, 2024 11:00 am
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
- May 1st, 2024 1:30 pm
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
- May 1st, 2024 12:30 pm
Alkermes plc Reports First Quarter 2024 Financial Results
- May 1st, 2024 11:00 am
How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?
- Apr 30th, 2024 12:00 pm
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Apr 24th, 2024 2:01 pm
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
- Apr 24th, 2024 11:00 am
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
- Apr 22nd, 2024 6:14 pm
Alkermes to Report First Quarter Financial Results on May 1, 2024
- Apr 17th, 2024 8:00 pm
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
- Apr 17th, 2024 2:01 pm
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
- Apr 16th, 2024 1:40 pm
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
- Apr 11th, 2024 2:15 pm
Alkermes' Innovations Are Transforming Mental Health Treatments
- Apr 11th, 2024 2:00 pm
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
- Apr 10th, 2024 1:45 pm
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
- Apr 9th, 2024 11:00 am
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
- Apr 8th, 2024 11:00 am
Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again
- Apr 2nd, 2024 4:10 pm
Scroll